drugset / Trial / NCT00004654
Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia
Phase 3
Completed
60 enrolled
National Center for Research Resources (NCRR)
Yale University · collab
RandomizedCrossoverTreatment
Summary
OBJECTIVES: I. Evaluate migraine prophylaxis with soy protein isolate in patients with hereditary hemorrhagic telangiectasia. II. Assess whether soy protein isolate reduces the frequency and severity of epistaxis and gastrointestinal bleeding in these patients.
Timeline
- Start
- 1996-01
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | soy protein | Protein / enzyme biologic | — | — |